Outcomes of <i>TP53</i>‐mutant acute myeloid leukemia with decitabine and venetoclaxKunhwa Kim, Marina Konopleva, Abhishek Maiti et al.|Cancer|2021Cited by 159
Venetoclax resistance: mechanistic insights and future strategiesFaustine Ong, Marina Konopleva, Kunhwa Kim|Cancer Drug Resistance|2022Cited by 103
Phase II study of azacitidine with pembrolizumab in patients with intermediate‐1 or higher‐risk myelodysplastic syndromeKelly S. Chien, Guillermo Garcia‐Manero, Kunhwa Kim et al.|British Journal of Haematology|2021Cited by 64
Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared AutoantigenSoung-Chul Cha, Sattva S. Neelapu, Hong Qin et al.|The Journal of Immunology|2013Cited by 54
AIM1 is an actin-binding protein that suppresses cell migration and micrometastatic disseminationMichael C. Haffner, Srinivasan Yegnasubramanian, David Esopi et al.|Nature Communications|2017Cited by 50